<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:47:28Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8166434" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8166434</identifier>
        <datestamp>2021-06-01</datestamp>
        <setSpec>neurology</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Neurology</journal-id>
              <journal-id journal-id-type="iso-abbrev">Neurology</journal-id>
              <journal-id journal-id-type="hwp">neurology</journal-id>
              <journal-id journal-id-type="publisher-id">neur</journal-id>
              <journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id>
              <journal-title-group>
                <journal-title>Neurology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0028-3878</issn>
              <issn pub-type="epub">1526-632X</issn>
              <publisher>
                <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
                <publisher-loc>Hagerstown, MD</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8166434</article-id>
              <article-id pub-id-type="pmcid">PMC8166434</article-id>
              <article-id pub-id-type="pmc-uid">8166434</article-id>
              <article-id pub-id-type="pmid">33827960</article-id>
              <article-id pub-id-type="pmid">33827960</article-id>
              <article-id pub-id-type="publisher-id">NEUROLOGY2019016329</article-id>
              <article-id pub-id-type="doi">10.1212/WNL.0000000000011848</article-id>
              <article-id pub-id-type="art-access-id">00009</article-id>
              <article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version>
              <article-categories>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>17</subject>
                  <subject>23</subject>
                  <subject>29</subject>
                  <subject>39</subject>
                  <subject>321</subject>
                  <subject>205</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1308-646X</contrib-id>
                  <name>
                    <surname>Rojas</surname>
                    <given-names>Julio C.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wang</surname>
                    <given-names>Ping</given-names>
                  </name>
                  <degrees>MS</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Staffaroni</surname>
                    <given-names>Adam M.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Heller</surname>
                    <given-names>Carolin</given-names>
                  </name>
                  <degrees>BSc</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0354-4092</contrib-id>
                  <name>
                    <surname>Cobigo</surname>
                    <given-names>Yann</given-names>
                  </name>
                  <degrees>PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wolf</surname>
                    <given-names>Amy</given-names>
                  </name>
                  <degrees>BS</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Goh</surname>
                    <given-names>Sheng-Yang M.</given-names>
                  </name>
                  <degrees>BS</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ljubenkov</surname>
                    <given-names>Peter A.</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Heuer</surname>
                    <given-names>Hilary W.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3637-8526</contrib-id>
                  <name>
                    <surname>Fong</surname>
                    <given-names>Jamie C.</given-names>
                  </name>
                  <degrees>MS</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Taylor</surname>
                    <given-names>Joanne B.</given-names>
                  </name>
                  <degrees>MS</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Veras</surname>
                    <given-names>Eliseo</given-names>
                  </name>
                  <degrees>BS</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Song</surname>
                    <given-names>Linan</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jeromin</surname>
                    <given-names>Andreas</given-names>
                  </name>
                  <degrees>PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hanlon</surname>
                    <given-names>David</given-names>
                  </name>
                  <degrees>PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Yu</surname>
                    <given-names>Lili</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Khinikar</surname>
                    <given-names>Arvind</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sivasankaran</surname>
                    <given-names>Rajeev</given-names>
                  </name>
                  <degrees>PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kieloch</surname>
                    <given-names>Agnieszka</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Valentin</surname>
                    <given-names>Marie-Anne</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Karydas</surname>
                    <given-names>Anna M.</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mitic</surname>
                    <given-names>Laura L.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pearlman</surname>
                    <given-names>Rodney</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kornak</surname>
                    <given-names>John</given-names>
                  </name>
                  <degrees>PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kramer</surname>
                    <given-names>Joel H.</given-names>
                  </name>
                  <degrees>PsyD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Miller</surname>
                    <given-names>Bruce L.</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kantarci</surname>
                    <given-names>Kejal</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Knopman</surname>
                    <given-names>David S.</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Graff-Radford</surname>
                    <given-names>Neill</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Petrucelli</surname>
                    <given-names>Leonard</given-names>
                  </name>
                  <degrees>PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rademakers</surname>
                    <given-names>Rosa</given-names>
                  </name>
                  <degrees>PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Irwin</surname>
                    <given-names>David J.</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Grossman</surname>
                    <given-names>Murray</given-names>
                  </name>
                  <degrees>MD, EdD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ramos</surname>
                    <given-names>Eliana Marisa</given-names>
                  </name>
                  <degrees>PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2105-1061</contrib-id>
                  <name>
                    <surname>Coppola</surname>
                    <given-names>Giovanni</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mendez</surname>
                    <given-names>Mario F.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bordelon</surname>
                    <given-names>Yvette</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5958-3445</contrib-id>
                  <name>
                    <surname>Dickerson</surname>
                    <given-names>Bradford C.</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6680-6731</contrib-id>
                  <name>
                    <surname>Ghoshal</surname>
                    <given-names>Nupur</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Huey</surname>
                    <given-names>Edward D.</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mackenzie</surname>
                    <given-names>Ian R.</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Appleby</surname>
                    <given-names>Brian S.</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Domoto-Reilly</surname>
                    <given-names>Kimiko</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8017-0856</contrib-id>
                  <name>
                    <surname>Hsiung</surname>
                    <given-names>Ging-Yuek R.</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Toga</surname>
                    <given-names>Arthur W.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Weintraub</surname>
                    <given-names>Sandra</given-names>
                  </name>
                  <degrees>PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kaufer</surname>
                    <given-names>Daniel I.</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kerwin</surname>
                    <given-names>Diana</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Litvan</surname>
                    <given-names>Irene</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2255-4437</contrib-id>
                  <name>
                    <surname>Onyike</surname>
                    <given-names>Chiadikaobi U.</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6427-7485</contrib-id>
                  <name>
                    <surname>Pantelyat</surname>
                    <given-names>Alexander</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1810-9763</contrib-id>
                  <name>
                    <surname>Roberson</surname>
                    <given-names>Erik D.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tartaglia</surname>
                    <given-names>Maria C.</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Foroud</surname>
                    <given-names>Tatiana</given-names>
                  </name>
                  <degrees>PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chen</surname>
                    <given-names>Weiping</given-names>
                  </name>
                  <degrees>MS</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Czerkowicz</surname>
                    <given-names>Julie</given-names>
                  </name>
                  <degrees>MS</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Graham</surname>
                    <given-names>Danielle L.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>van Swieten</surname>
                    <given-names>John C.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Borroni</surname>
                    <given-names>Barbara</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sanchez-Valle</surname>
                    <given-names>Raquel</given-names>
                  </name>
                  <degrees>PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Moreno</surname>
                    <given-names>Fermin</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2031-490X</contrib-id>
                  <name>
                    <surname>Laforce</surname>
                    <given-names>Robert</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Graff</surname>
                    <given-names>Caroline</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Synofzik</surname>
                    <given-names>Matthis</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9284-5953</contrib-id>
                  <name>
                    <surname>Galimberti</surname>
                    <given-names>Daniela</given-names>
                  </name>
                  <degrees>PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rowe</surname>
                    <given-names>James B.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Masellis</surname>
                    <given-names>Mario</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Finger</surname>
                    <given-names>Elizabeth</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6237-2502</contrib-id>
                  <name>
                    <surname>Vandenberghe</surname>
                    <given-names>Rik</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>de Mendonça</surname>
                    <given-names>Alexandre</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tagliavini</surname>
                    <given-names>Fabrizio</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Santana</surname>
                    <given-names>Isabel</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ducharme</surname>
                    <given-names>Simon</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Butler</surname>
                    <given-names>Chris R.</given-names>
                  </name>
                  <degrees>PhD, FRCP</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gerhard</surname>
                    <given-names>Alexander</given-names>
                  </name>
                  <degrees>MD, MRCP</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Levin</surname>
                    <given-names>Johannes</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8857-5383</contrib-id>
                  <name>
                    <surname>Danek</surname>
                    <given-names>Adrian</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4273-4267</contrib-id>
                  <name>
                    <surname>Otto</surname>
                    <given-names>Markus</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sorbi</surname>
                    <given-names>Sandro</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7833-616X</contrib-id>
                  <name>
                    <surname>Cash</surname>
                    <given-names>David M.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Convery</surname>
                    <given-names>Rhian S.</given-names>
                  </name>
                  <degrees>MSc</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bocchetta</surname>
                    <given-names>Martina</given-names>
                  </name>
                  <degrees>PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Foiani</surname>
                    <given-names>Martha</given-names>
                  </name>
                  <degrees>MRes</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Greaves</surname>
                    <given-names>Caroline V.</given-names>
                  </name>
                  <degrees>BSc</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3319-138X</contrib-id>
                  <name>
                    <surname>Peakman</surname>
                    <given-names>Georgia</given-names>
                  </name>
                  <degrees>MSc</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Russell</surname>
                    <given-names>Lucy</given-names>
                  </name>
                  <degrees>PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Swift</surname>
                    <given-names>Imogen</given-names>
                  </name>
                  <degrees>MSc</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1551-5691</contrib-id>
                  <name>
                    <surname>Todd</surname>
                    <given-names>Emily</given-names>
                  </name>
                  <degrees>MRes</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rohrer</surname>
                    <given-names>Jonathan D.</given-names>
                  </name>
                  <degrees>PhD, FRCP</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Boeve</surname>
                    <given-names>Bradley F.</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rosen</surname>
                    <given-names>Howard J.</given-names>
                  </name>
                  <degrees>MD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Boxer</surname>
                    <given-names>Adam L.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <collab>on behalf of the ALLFTD and GENFI consortia</collab>
                </contrib>
                <aff>From the University of California, San Francisco (J.C.R., P.W., A.M.S., Y.C., A.W., S.-Y.M.G., P.A.L., H.W.H., J.C.F., J.B.T., A.M.K., L.L.M., J.K., J.H.K., B.L.M., H.J.S., A.L.B.); UK Dementia Research Centre (C.H., D.M.C., R.S.C., M.B., M.F., C.V.G., G.P., L.R., I.S., E.T., J.D.R.), UCL Institute of Neurology, Queen Square, London; Quanterix Corp (E.V., L.S., A.J., D.H.), Lexington; Novartis Institutes for Biomedical Research Inc (L.Y., A. Khinikar, R.S.), Cambridge, MA; Novartis Pharma AG (A. Kieloch, M.-A.V.), Basel, <country>Switzerland;</country> Bluefield Project to Cure Frontotemporal Dementia (L.L.M., R.P.), San Francisco, CA; Mayo Clinic (K.K., D.S.K., B.F.B.), Rochester, MN; Mayo Clinic (N.G.-R., L.P., R.R.), Jacksonville, FL; University of Pennsylvania (D.J.I., M.G.), Philadelphia; University of California, Los Angeles (E.M.R., G.C., M.F.M., Y.B.); Harvard University/Massachusetts General Hospital (B.D.C.), Boston, MA; Washington University (N.G.), St. Louis, MO; Columbia University (E.D.H.), New York, NY; University of British Columbia (I.R.M., G.-Y.R.H.), Vancouver, <country>Canada;</country> Case Western Reserve University (B.S.A.), Cleveland, OH; University of Washington (K.D.-R.), Seattle; Laboratory of Neuroimaging (A.W.T.), University of Southern California, Los Angeles; Northwestern University (S.W.), Chicago, IL; University of North Carolina (D.I.K.), Chapel Hill; Texas Health Presbyterian Hospital Dallas (D.K.); University of California, San Diego (I.L.); Johns Hopkins Hospital (C.U.O., A.P.), Baltimore, MD; University of Alabama at Birmingham (E.D.R.); University of Toronto (M.C.T., M.M.), Ontario, <country>Canada;</country> Indiana University School of Medicine (T.F.), Indianapolis; Biogen Inc (W.C., J.C., D.L.G.), Cambridge, MA; Erasmus Medical Centre (J.C.v.S.), Rotterdam, the <country>Netherlands;</country> University of Brescia (B.B.), <country>Italy;</country> University of Barcelona (R.S.-V.)<country>;</country> Donostia University Hospital (F.M.), San Sebastian, Gipuzkoa, <country>Spain;</country> Clinique Interdisciplinaire de Mémoire (R.L.), Département des Sciences Neurologiques, CHU de Québec; Faculté de Médecine (R.L.), Université Laval, Quebec, <country>Canada;</country> Center for Alzheimer Research (C.G.), Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Bioclinicum, Karolinska Institutet; Unit for Hereditary Dementias (C.G.), Theme Aging, Karolinska University Hospital, Solna, <country>Sweden;</country> University of Tübingen (M.S.); Center for Neurodegenerative Diseases (DZNE) (M.S.), Tübingen, <country>Germany;</country> Fondazione IRCCS Ospedale Policlinico (D.G.); University of Milan (D.G.), Centro Dino Ferrari, <country>Italy;</country> Department of Clinical Neurosciences and Cambridge University Hospital (J.B.R.), University of Cambridge, <country>UK;</country> University of Western Ontario (E.F.), London, <country>Canada;</country> KU Leuven (R.V.), Belgium; Neurology Service (R.V.), University Hospitals Leuven, <country>Belgium;</country> University of Lisbon (A.d.M.), <country>Portugal;</country> Fondazione IRCCS Istituto Neurologico Carlo Besta (F.T.), Milan, <country>Italy;</country> University of Coimbra (I.S.), <country>Portugal;</country> McGill University (S.D.), Montreal, Québec, <country>Canada;</country> University of Oxford (C.R.B.)<country>;</country> Wolfson Molecular Imaging Centre (A.G.), University of Manchester, UK; University of Duisburg-Essen (A.G.), Duisberg; Ludwig-Maximilians-Universität München (J.L., A.D.); German Center for Neurodegenerative Diseases (J.L.), Munich Cluster for Systems Neurology (SyNergy)<country>;</country> University of Ulm (M.O.), <country>Germany; and</country> Department of Neuroscience, Psychology, Drug Research and Child Health (S.S.), University of Florence, and IRCCS Fondazione Don Carlo Gnocchi, Florence, <country>Italy.</country></aff>
              </contrib-group>
              <author-notes>
                <corresp><bold>Correspondence</bold> Dr. Rojas <email>jrojasmartinez@memory.ucsf.edu</email></corresp>
                <fn fn-type="financial-disclosure">
                  <p>Go to <ext-link xlink:href="https://n.neurology.org/lookup/doi/10.1212/WNL.0000000000011848" ext-link-type="uri">Neurology.org/N</ext-link> for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.</p>
                </fn>
                <fn fn-type="other">
                  <p>Coinvestigators are listed in the <xref rid="A2" ref-type="app">Appendixes 2</xref> and <xref rid="A3" ref-type="app">3</xref> at <ext-link xlink:href="http://links.lww.com/WNL/B350" ext-link-type="uri" specific-use="external-ds">links.lww.com/WNL/B350</ext-link> and <ext-link xlink:href="http://links.lww.com/WNL/B351" ext-link-type="uri" specific-use="external-ds">links.lww.com/WNL/B351</ext-link>.</p>
                </fn>
                <fn fn-type="other">
                  <p>The Article Processing Charge was funded by the NIH.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="ppub">
                <day>4</day>
                <month>5</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>4</day>
                <month>5</month>
                <year>2021</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="ppub"/>.-->
              <volume>96</volume>
              <issue>18</issue>
              <fpage>e2296</fpage>
              <lpage>e2312</lpage>
              <history>
                <date date-type="received">
                  <day>25</day>
                  <month>7</month>
                  <year>2019</year>
                </date>
                <date date-type="accepted">
                  <day>08</day>
                  <month>2</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>American Academy of Neurology</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CC BY)</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="NEUROLOGY2019016329.pdf"/>
              <abstract>
                <sec>
                  <title>Objective</title>
                  <p>We tested the hypothesis that plasma neurofilament light chain (NfL) identifies asymptomatic carriers of familial frontotemporal lobar degeneration (FTLD)–causing mutations at risk of disease progression.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p>Baseline plasma NfL concentrations were measured with single-molecule array in original (n = 277) and validation (n = 297) cohorts. <italic toggle="yes">C9orf72</italic>, <italic toggle="yes">GRN</italic>, and <italic toggle="yes">MAPT</italic> mutation carriers and noncarriers from the same families were classified by disease severity (asymptomatic, prodromal, and full phenotype) using the CDR Dementia Staging Instrument plus behavior and language domains from the National Alzheimer's Disease Coordinating Center FTLD module (CDR+NACC-FTLD). Linear mixed-effect models related NfL to clinical variables.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>In both cohorts, baseline NfL was higher in asymptomatic mutation carriers who showed phenoconversion or disease progression compared to nonprogressors (original: 11.4 ± 7 pg/mL vs 6.7 ± 5 pg/mL, <italic toggle="yes">p</italic> = 0.002; validation: 14.1 ± 12 pg/mL vs 8.7 ± 6 pg/mL, <italic toggle="yes">p</italic> = 0.035). Plasma NfL discriminated symptomatic from asymptomatic mutation carriers or those with prodromal disease (original cutoff: 13.6 pg/mL, 87.5% sensitivity, 82.7% specificity; validation cutoff: 19.8 pg/mL, 87.4% sensitivity, 84.3% specificity). Higher baseline NfL correlated with worse longitudinal CDR+NACC-FTLD sum of boxes scores, neuropsychological function, and atrophy, regardless of genotype or disease severity, including asymptomatic mutation carriers.</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p>Plasma NfL identifies asymptomatic carriers of FTLD-causing mutations at short-term risk of disease progression and is a potential tool to select participants for prevention clinical trials.</p>
                </sec>
                <sec>
                  <title>Trial Registration Information</title>
                  <p>ClinicalTrials.gov Identifier: NCT02372773 and NCT02365922.</p>
                </sec>
                <sec>
                  <title>Classification of Evidence</title>
                  <p>This study provides Class I evidence that in carriers of FTLD-causing mutations, elevation of plasma NfL predicts short-term risk of clinical progression.</p>
                </sec>
              </abstract>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>OPEN-ACCESS</meta-name>
                  <meta-value>TRUE</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>STATUS</meta-name>
                  <meta-value>ONLINE-ONLY</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <p>Blood-based biomarkers are uniquely valuable for therapeutic development because they are easily obtainable and relatively inexpensive.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Frontotemporal lobar degeneration (FTLD) produces behavioral, cognitive, language, and motor deficits that impair the quality of life of patients and caregivers more severely than other forms of dementia.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> About 20% to 30% of FTLD cases are familial, and ≈60% of those are caused by autosomal dominant mutations in 3 genes<sup><xref rid="R3" ref-type="bibr">3</xref></sup>: chromosome 9 open reading frame 72 (<italic toggle="yes">C9orf72</italic>),<sup><xref rid="R4" ref-type="bibr">4</xref></sup> progranulin (<italic toggle="yes">GRN</italic>),<sup><xref rid="R5" ref-type="bibr">5</xref></sup> and microtubule-associated protein tau (<italic toggle="yes">MAPT</italic>).<sup><xref rid="R6" ref-type="bibr">6</xref></sup> Several therapies are poised to begin clinical trials for familial FTLD (f-FTLD) due to these mutations.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> Planning such studies is challenging due to the low f-FTLD prevalence and the lack of good clinical endpoints to monitor disease severity and therapeutic response.</p>
            <p>Neurofilament light chain (NfL) is a sensitive marker of neurodegeneration.<sup><xref rid="R8" ref-type="bibr">8</xref></sup> CSF NfL is elevated in patients with FTLD compared to patients with Alzheimer disease and healthy controls,<sup><xref rid="R9" ref-type="bibr">9</xref><xref rid="R10" ref-type="bibr">-</xref><xref rid="R12" ref-type="bibr">12</xref></sup> with concentrations that correlate with disease severity, cognitive function, and disease progression.<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup> CSF NfL concentrations normalize on effective treatment in multiple sclerosis<sup><xref rid="R15" ref-type="bibr">15</xref></sup> and spinal muscle atrophy,<sup><xref rid="R16" ref-type="bibr">16</xref></sup> suggesting that NfL is sensitive to treatment effects. Serum NfL is elevated in FTLD,<sup><xref rid="R17" ref-type="bibr">17</xref></sup> and in symptomatic carriers of f-FTLD–causing mutations, concentrations correlate with brain atrophy.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> We tested the hypothesis that plasma NfL could identify asymptomatic f-FTLD mutation carriers at high risk of progression to symptomatic disease. We examined baseline plasma NfL differences related to phenotype, genotype, and disease severity and whether it predicts disease progression in 2 independent cohorts.</p>
            <sec sec-type="methods" id="s1">
              <title>Methods</title>
              <p>The primary research question was the following: do plasma NfL concentrations identify f-FTLD mutation carriers at risk of clinical progression (Class I level of evidence)?</p>
              <sec id="s1-1">
                <title>Standard Protocol Approvals, Registrations, and Patient Consents</title>
                <p>Participants or their caregivers provided written informed consent, and the study procedures were approved by the local Institutional Review Board committees at each of the participating centers. Patients were recruited through the North American multicenter observational studies Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS; <ext-link xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> NCT02372773) and Advancing Research and Treatment in Frontotemporal Lobar Degeneration (ARTFL; <ext-link xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> NCT02365922)<sup><xref rid="R19" ref-type="bibr">19</xref></sup> and the Genetic Frontotemporal Dementia Initiative (GENFI).<sup><xref rid="R20" ref-type="bibr">20</xref></sup></p>
              </sec>
              <sec id="s1-2">
                <title>Participants</title>
                <p>Participants were divided into original (LEFFTDS/ARTFL, n = 277) and validation (GENFI, n = 297) cohorts. LEFFTDS/ARTFL is a North American network of 19 clinical research centers. LEFFTDS enrolled members of families with a known mutation in 1 of the 3 major FTLD genes: <italic toggle="yes">C9orf72</italic>, <italic toggle="yes">GRN</italic>, and <italic toggle="yes">MAPT</italic>. ARTFL enrolled participants who met research criteria for an FTLD syndrome and asymptomatic individuals with a family history of an FTLD syndrome, regardless of whether an FTLD-causing mutation had been identified in the family.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> On evaluation, some participants with a family history of FTLD were determined to have prodromal disease or mild cognitive or behavioral impairment (MBI/MCI), as defined previously.<sup><xref rid="R21" ref-type="bibr">21</xref></sup> GENFI involves 25 research centers across Europe and Canada and enrolls symptomatic carriers of mutations in the 3 major FTLD genes with frontotemporal dementia and those at risk of carrying a mutation because a first-degree relative is a known symptomatic carrier. Both cohorts consisted of participants with available baseline NfL concentrations, known genotype, and CDR Dementia Staging Instrument plus behavior and language domains from the National Alzheimer's Disease Coordinating Center FTLD module (CDR+NACC-FTLD) global and sum of boxes (sb) scores.<sup><xref rid="R21" ref-type="bibr">21</xref></sup> Mutation noncarriers with CDR+NACC-FTLD global score &gt;0 were excluded (11 in the original cohort and 22 in the validation cohort). The validation cohort data have been reported previously.<sup><xref rid="R22" ref-type="bibr">22</xref></sup> In the original cohort, clinically defined phenotypes included 184 normal (66.7%), 12 mild behavioral impairment (4.3%), 16 mild cognitive impairment (5.8%), 3 amnestic dementia (1.1%), 48 behavioral variant frontotemporal dementia (bvFTD; 17.4%), 7 frontotemporal dementia with amyotrophic lateral sclerosis (FTD/ALS; 2.5%), 4 primary progressive aphasia (PPA; nonfluent or semantic, 1.4%), and 3 corticobasal syndrome (CBS; 1.1%). Participants in the validation cohort included 240 normal (80.8%), 36 bvFTD (12.1%), 6 FTD/ALS (2%), 3 CBS (1%), and 12 PPA (4%). Data on whether there was conversion from asymptomatic to MBI/MCI or full phenotype or from MBI/MCI to full phenotype were available in 221 of 277 participants in the original cohort and in 159 of 297 participants in the validation cohort.</p>
              </sec>
              <sec id="s1-3">
                <title>Clinical Procedures</title>
                <p>Participants underwent annual standardized evaluations that included neurologic assessment, caregiver or companion interview, neuropsychological testing, brain MRI, and biofluid collection for up to 3 years in the original cohort and for 2 years in the validation cohort. Clinical scales included CDR+NACC-FTLD global and CDR+NACC-FTLDsb<sup><xref rid="R21" ref-type="bibr">21</xref></sup> and Clinical Global Impression of Severity (CGI-S),<sup><xref rid="R23" ref-type="bibr">23</xref></sup> which are based on semistructured interviews and provide global measures of clinical severity; Montreal Cognitive Assessment (MoCA); Unified Parkinson's Disease Rating Scale III, Motor Section<sup><xref rid="R24" ref-type="bibr">24</xref></sup>; Schwab and England Activities of Daily Living (SEADL), for measurement of impairment in activities of daily living<sup><xref rid="R25" ref-type="bibr">25</xref></sup>; Functional Assessment Scale (FAS), for assessment of impairment in instrumental activities<sup><xref rid="R26" ref-type="bibr">26</xref></sup>; and Neuropsychiatric Inventory.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> CDR+NACC-FTLD and Mini-Mental State Examination (MMSE) were the only severity scales available in the validation cohort. Neuropsychological testing available in both cohorts included the California Verbal Learning Test–Short Form, immediate and delayed recall<sup><xref rid="R28" ref-type="bibr">28</xref></sup>; the Benson figure recall<sup><xref rid="R29" ref-type="bibr">29</xref></sup>; forward and backward digit span; number of correct trials; Trail-Making Test Parts A and B (time to completion)<sup><xref rid="R30" ref-type="bibr">30</xref></sup>; and phonemic and semantic fluency. In the original cohort, blood samples were centrifuged at 1,500<italic toggle="yes">g</italic> at 4°C for 15 minutes. Plasma was aliquoted in 1,000-μl vials and stored at −80°C at the National Centralized Repository for Alzheimer's Disease and Related Dementias. In the validation cohort, blood samples were collected and processed as previously reported.<sup><xref rid="R22" ref-type="bibr">22</xref></sup> Genetic screening was conducted to identify FTLD-causing mutations in the <italic toggle="yes">C9orf72</italic>, <italic toggle="yes">GRN</italic>, and <italic toggle="yes">MAPT</italic> genes and <italic toggle="yes">APOE</italic> polymorphisms as described previously.<sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R31" ref-type="bibr">31</xref></sup></p>
              </sec>
              <sec id="s1-4">
                <title>Plasma NfL Measurement</title>
                <p>In the original cohort, plasma NfL concentrations were measured at baseline with single-molecule array technology (Simoa), using the commercially available NF-light digital immunoassay kit (Quanterix, Lexington, MA). Plasma samples were thawed at room temperature (1 cycle), mixed thoroughly, and centrifuged at 14,000<italic toggle="yes">g</italic> for 3 minutes. The supernatant was loaded onto a Quanterix HD-1 Analyzer with a 1:4 specified dilution. Measures were completed in duplicate over a total of 6 batches, each with an 8-point calibration curve tested in triplicate and 2 controls tested in duplicate. Plasma concentrations were interpolated from the calibration curve within the same batch and corrected for the dilution. All samples were quantifiable within the dynamic range of 0.69 to 2,000 pg/mL and with an average coefficient of variation of 6.5%. Measurements were completed using the same platform in 2 centers: Quanterix (n = 226, February 2018) and Novartis Institutes for Biomedical Research (n = 64, July 2018). Samples from a subset of 186 participants were analyzed twice, independently by each center, with plasma NfL concentrations that were highly correlated (<italic toggle="yes">r</italic> = 0.98, <italic toggle="yes">p</italic> &lt; 0.001). The samples analyzed by the 2 centers also had comparable means and SDs (Quanterix 21.8 ± 35 pg/mL and Novartis 20.2 ± 34 pg/mL), and there were no differences in the median plasma NfL concentrations in 2 groups of age-matched asymptomatic noncarrier controls measured separately (Quanterix 6.9 ± 4 pg/mL, n = 38 vs Novartis 6.4 ± 6 pg/mL, n = 50, <italic toggle="yes">p</italic> = 0.6). The center where samples were analyzed was added as a covariate in statistical analyses. Instrument operators were blinded to clinical and genetic information. In the validation cohort, plasma NfL concentrations were measured with the multiplex Simoa Neurology 4-Plex A kit.<sup><xref rid="R22" ref-type="bibr">22</xref></sup></p>
              </sec>
              <sec id="s1-5">
                <title>CSF Biomarker Measurements</title>
                <p>CSF biomarkers were available in 113 of the 277 participants at baseline in the original cohort only. Using fit-for-purpose immunoassays, CSF samples were analyzed for NfL, tau, phosphorylated tau<sub>181</sub> (p-tau), neurogranin, and phosphorylated neurofilament heavy chain (p-NfH) at the following dilutions, 1:50, neat, 1:20, neat, and 1:4, respectively. NfL and tau were measured on the Quanterix Simoa HD-1 (catalog Nos. 103186 and 101552, respectively); p-tau was measured with the Innotest kit (catalog No. 81581); neurogranin was measured with the Euroimmun kit (item code EQ-6551-9601-L); and p-NfH was measured on the Protein Simple Ella platform (catalog No. SPCKB-PS-000519). Measurements were conducted by an independent laboratory with operators blinded to clinical data (Biogen, Inc, Cambridge, MA).</p>
              </sec>
              <sec id="s1-6">
                <title>Neuroimaging</title>
                <p>Brain MRI was obtained in the original cohort as described previously<sup><xref rid="R32" ref-type="bibr">32</xref></sup> within 45 days of plasma collection except for 15 patients for whom images were obtained within &gt;45 days of plasma collection (median 60 days, range 50–423 days). To simplify relationships with plasma NfL and to control for multiple comparisons, bilateral frontal and temporal gray matter lobar composites were created with regions of interest involved in FTLD syndromes. Frontal regions included frontal pole, lateral orbitofrontal cortex, medial orbitofrontal cortex, middle frontal gyrus, pars opercularis, pars orbitalis, pars triangularis, superior frontal gyrus, and precentral gyrus. Anterior cingulate (caudal and rostral) and insula were also included in the frontal composite, given their significant involvement in FTLD.<sup><xref rid="R33" ref-type="bibr">33</xref></sup> Temporal regions included banks of the superior temporal sulcus, entorhinal cortex, fusiform gyrus, middle temporal gyrus, parahippocampal cortex, superior temporal gyrus, temporal pole, and transverse temporal gyrus.</p>
              </sec>
              <sec id="s1-7">
                <title>Statistical Analyses</title>
                <p>Biofluid measurements, disease status determination, and statistical analyses were performed separately by different investigators. Original and validation cohort data were handled independently. Data were visually explored with boxplots. NfL data were not normally distributed. Group differences in NfL concentrations were determined with nonparametric tests. Log-transformed NfL data were used as outcome in general linear models to determine between-group differences in NfL concentrations corrected for age and sex. Receiver operating characteristic (ROC) curves tested the diagnostic accuracy of plasma NfL concentrations. Combined forward and backward stepwise linear regressions controlling for age, sex, and genotype determined baseline associations between plasma NfL and clinical variables. Starting with minimal models, the stepwise criteria were such that a variable entered a model when <italic toggle="yes">p</italic> &lt; 0.05, and it was removed when <italic toggle="yes">p</italic> ≥ 0.1. For associations with gray matter volumes, total intracranial volume was an additional control variable.<sup><xref rid="R32" ref-type="bibr">32</xref></sup> Linear mixed models tested the ability of baseline log plasma NfL to predict change in clinical variables. All models included interaction terms of log plasma NfL with time as a discrete predictor. Models used compound symmetry covariance and random slopes and intercepts and were controlled for by sex, age, genotype, clinical center, and, when modeling prediction of gray matter volumes, total intracranial volume. Models were run with log plasma NfL as a continuous independent variable and subsequently as a categorical independent variable based on cutoff points derived from Youden indices estimated with ROC curves. Models were run separately for each of the disease severity levels defined by the CDR+NACC-FTLD global score: normal or asymptomatic (carriers and noncarriers run independently) (0), MBI/MCI or prodromal disease (0.5), and dementia or full phenotype (≥1).<sup><xref rid="R21" ref-type="bibr">21</xref></sup> Model results were corrected for multiple comparisons across dependent variables for a given disease severity level using false discovery rate.<sup><xref rid="R34" ref-type="bibr">34</xref></sup> Analyses were done with SPSS Statistics software, version 26 (IBM, Armonk, NY) and GraphPad Prism, version 8.4 (GraphPad, La Jolla, CA).</p>
              </sec>
              <sec sec-type="data-availability" id="s1-8">
                <title>Data Availability</title>
                <p>Joint ARTFL and LEFFTDS data and biospecimens and GENFI data are available to qualified investigators for replication of the present study results or further projects.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="s2">
              <title>Results</title>
              <sec id="s2-1">
                <title>Group Differences in Baseline Plasma NfL Concentrations, Original Cohort</title>
                <p>Of 277 individuals with baseline evaluations (<xref rid="T1" ref-type="table">table 1</xref>), 221 (79.7%) and 148 (53.4%) also had follow-up data available for years 1 and 2, respectively. In all genotypes combined and after correction for age and sex, amnestic dementia, bvFTD, FTD/ALS, CBS, and PPA phenotypes had higher plasma NfL concentrations than asymptomatic participants (mutation carriers and noncarriers combined) and those with MCI (<xref rid="F1" ref-type="fig">figure 1</xref>).</p>
                <table-wrap position="float" id="T1">
                  <label>Table 1</label>
                  <caption>
                    <p>Baseline Demographic Characteristics by Disease Severity, Original Cohort<sup>ae</sup></p>
                  </caption>
                  <graphic xlink:href="NEUROLOGY2019016329TT1" position="float"/>
                </table-wrap>
                <fig position="float" id="F1">
                  <label>Figure 1</label>
                  <caption>
                    <title>Baseline Plasma NfL Chain Concentrations by Clinical Phenotype</title>
                    <p>(A) Original (Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects [LEFFTDS]/Advancing Research and Treatment in Frontotemporal Lobar Degeneration [ARTFL]) cohort. (B) Validation (Genetic Frontotemporal Dementia Initiative [GENFI]) cohort. Phenotypes are based on clinical diagnosis and did not rely on severity scales. Only the original cohort included clinically diagnosed prodromal disease (mild behavioral impairment [MBI] or mild cognitive impairment [MCI]). Horizontal bars represent median values. Upper and lower quartiles are delimitated by the boxes. Lowest and highest values are indicated by whiskers. bvFTD = behavioral variant frontotemporal dementia; CBS = corticobasal syndrome; FTD/ALS = frontotemporal dementia with amyotrophic lateral sclerosis; NfL = neurofilament light chain; PPA = primary progressive aphasia (nonfluent or semantic). *Compared to normal. **Compared to normal and MCI, <italic toggle="yes">p</italic> &lt; 0.05.</p>
                  </caption>
                  <graphic xlink:href="NEUROLOGY2019016329FF1" position="float"/>
                </fig>
                <p>As defined by disease severity, 65.7% of the participants (33.2% carriers and 32.5% noncarriers) were asymptomatic (CDR+NACC-FTLD score 0), 11.9% had MBI/MCI (CDR+NACC-FTLD score 0.5), and 22.4% had full phenotype (CDR+NACC-FTLD score ≥1). Median baseline plasma NfL concentrations were highest in participants with full phenotype (<xref rid="F2" ref-type="fig">figure 2</xref>). There were no differences in NfL concentrations between asymptomatic mutation carriers and noncarriers for any genotype. Median plasma NfL concentrations tended to be higher in those with MBI/MCI than asymptomatic mutation carriers, but the results did not reach statistical significance (12.2 ± 10 pg/mL vs 7.5 ± 6 pg/mL, <italic toggle="yes">p</italic> = 0.085, mean estimate difference 0.44, 95% confidence interval [CI] 0.85–0.99, <italic toggle="yes">p</italic> = 0.016) in all genotypes combined. In <italic toggle="yes">C9orf72</italic> carriers, NfL concentrations were higher in participants with MBI/MCI compared to asymptomatic individuals (13.6 ± 34 pg/mL vs 6.6 ± 5 pg/mL, <italic toggle="yes">p</italic> &lt; 0.001, <xref rid="F3" ref-type="fig">figure 3</xref>) but not in <italic toggle="yes">GRN</italic> or <italic toggle="yes">MAPT</italic>. There were no genotype-related differences in NfL in asymptomatic mutation carriers or those with MBI/MCI. In full phenotype, NfL was higher in <italic toggle="yes">GRN</italic> (61.5 ± 54 pg/mL) than in <italic toggle="yes">C9orf72</italic> (33.9 ± 33 pg/mL, <italic toggle="yes">p</italic> &lt; 0.001) and <italic toggle="yes">MAPT</italic> (20.5 ± 11 pg/mL, <italic toggle="yes">p</italic> &lt; 0.001).</p>
                <fig position="float" id="F2">
                  <label>Figure 2</label>
                  <caption>
                    <title>Baseline Plasma NfL Concentrations by Disease Severity and Diagnostic Performance</title>
                    <p>(A–C) Original (Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects [LEFFTDS]/Advancing Research and Treatment in Frontotemporal Lobar Degeneration [ARTFL]) cohort. (D–F) Validation (Genetic Frontotemporal Dementia Initiative [GENFI]) cohort. Severity was determined by the CDR Dementia Staging Instrument plus Behavior and Language domains from the National Alzheimer's Disease Coordinating Center Frontotemporal Lobar Degeneration module (CDR+NACC-FTLD). (A and D) Boxplots show plasma neurofilament light chain (NfL) concentrations in asymptomatic carriers (i.e., CDR+NACC-FTLD score 0), those with mild behavioral or cognitive impairment (mild behavioral impairment/mild cognitive impairment [MBI/MCI], CDR+NACC-FTLD score 0.5), and patients with full phenotypes (CDR+NACC-FTLD score ≥1). Horizontal bars represent median values. Upper and lower quartiles are delimitated by the boxes. Lowest and highest values are indicated by whiskers. (B and E) Receiver operating characteristic (ROC) curves show that plasma NfL was a good discriminator between individuals with full phenotype and those either asymptomatic or with MBI/MCI. (C and F) Proportion of patients with low or high plasma NfL concentrations, determined by the ROC curve, is presented for each disease severity. AUC = area under the curve.</p>
                  </caption>
                  <graphic xlink:href="NEUROLOGY2019016329FF2" position="float"/>
                </fig>
                <fig position="float" id="F3">
                  <label>Figure 3</label>
                  <caption>
                    <title>Plasma NfL Concentrations by Disease Severity in Each Genotype Group</title>
                    <p>(A–C) Original cohort. (D–F) Validation cohort. MBI/MCI = mild behavioral or cognitive impairment (CDR Dementia Staging Instrument plus Behavior and Language domains from the National Alzheimer's Disease Coordinating Center Frontotemporal Lobar Degeneration module score 0.5); <italic toggle="yes">C90rf72</italic> = chromosome 9 open reading frame 72; <italic toggle="yes">GRN</italic> = progranulin; <italic toggle="yes">MAPT</italic> = microtubule-associated protein tau; NC = noncarrier; NfL = neurofilament light chain.</p>
                  </caption>
                  <graphic xlink:href="NEUROLOGY2019016329FF3" position="float"/>
                </fig>
                <p>In all participants combined, a cut point of ≥13.6 pg/mL discriminated individuals with full phenotype from asymptomatic individuals or those with MBI/MCI with 87.5% sensitivity, 82.7% specificity, 59.7% positive predictive value, and 96.2% negative predictive value (area under the curve [AUC] 0.901, 95% CI 0.861–0.942, <italic toggle="yes">p</italic> &lt; 0.001). Plasma NfL was a poor discriminator between asymptomatic mutation carriers and those with MBI/MCI (AUC 0.676, 95% CI 0.588–0.724, <italic toggle="yes">p</italic> &lt; 0.001), but it was a better discriminator between participants with MBI/MCI and those with full phenotype (0.803, 95% CI 0.744–0.862, <italic toggle="yes">p</italic> &lt; 0.001). The proportion of participants with high (≥13.6 pg/mL) NfL differed by severity group: 12.2% in asymptomatic mutation noncarriers, 14.1% in asymptomatic mutation carriers, 39.4% in those with MBI/MCI, and 88.7% in those with full phenotype (χ<sup>2</sup> = 119.6, <italic toggle="yes">p</italic> &lt; 0.001).</p>
              </sec>
              <sec id="s2-2">
                <title>Baseline Correlations With Clinical Variables, Original Cohort</title>
                <p>Baseline NfL strongly correlated with age in the overall sample (ρ = 0.69, 95% CI 0.505–0.695, <italic toggle="yes">p</italic> &lt; 0.001) and in asymptomatic individuals (ρ = 0.63, 95% CI 0.437–0.769, <italic toggle="yes">p</italic> &lt; 0.001) and those with MBI/MCI (ρ = 0.71, 95% CI 0.364–0.917, <italic toggle="yes">p</italic> &lt; 0.001); it correlated weakly in individuals with full phenotype (ρ = 0.23, 95% CI −0.109 to 0.402, <italic toggle="yes">p</italic> = 0.07). NfL concentrations were higher in women than in men (10.7 ± 13 pg/mL vs 7.6 ± 9 pg/mL, mean estimate difference 0.75, 95% CI 0.59–0.95, <italic toggle="yes">p</italic> = 0.01), even after controlling for age, disease severity, and genotype (β = 0.251, 95% CI 0.092–0.409, <italic toggle="yes">p</italic> = 0.002). In all participants, plasma NfL was strongly associated with all clinical, neuropsychological, and gray matter volume variables at baseline. None of the relationships were affected by genotype, and they remained essentially unchanged after exclusion of asymptomatic noncarriers (eTable 1, <ext-link xlink:href="https://doi.org/10.7272/Q6W957CZ" ext-link-type="uri">doi.org/10.7272/Q6W957CZ</ext-link>). The strongest associations were observed with measures of disease severity, including CDR+NACC-FTLDsb, CGI-S, SEADL, and FAS scores. Weaker associations were observed with gray matter volumes. CSF biomarkers were available in 113 (40.7%) participants (34 asymptomatic noncarriers, 46 asymptomatic mutation carriers, 14 with MBI/MCI, and 19 with full phenotype). Plasma NfL correlated with CSF NfL (ρ = 0.74, <italic toggle="yes">p</italic> &lt; 0.001), CSF p-NfH (ρ = 0.73, <italic toggle="yes">p</italic> &lt; 0.001), and CSF tau (ρ = 0.45, <italic toggle="yes">p</italic> &lt; 0.001), but not with CSF neurogranin (ρ = 0.06, <italic toggle="yes">p</italic> = 0.94) or CSF p-tau (ρ = 0.07, p = 0.46). There were no differences in the proportion of <italic toggle="yes">APOE</italic> carriers as a function of clinical phenotype, genotype, or disease severity or differences in NfL concentrations by <italic toggle="yes">APOE</italic> genotype.</p>
              </sec>
              <sec id="s2-3">
                <title>Baseline NfL, Phenoconversion, and Disease Progression, Original Cohort</title>
                <p>Twenty-six mutation carriers phenoconverted after 2 years (15 asymptomatic [12 to MBI/MCI and 3 to full phenotype] and 11 MBI/MCI to full phenotype). Phenoconversion occurred in 10 of 21 (47.6%) of asymptomatic or MBI/MCI mutation carriers with baseline NfL ≥13.6 pg/mL compared to 16 of 84 (11.4%) of those with baseline NfL &lt;13.6 pg/mL (<italic toggle="yes">p</italic> = 0.007). Median baseline NfL concentrations were higher in asymptomatic mutation carriers who phenoconverted to either MBI/MCI or dementia over the next 2 years compared to those who remained asymptomatic (11.4 ± 7 pg/mL vs 6.7 ± 5 pg/mL, <italic toggle="yes">p</italic> = 0.002, <xref rid="F4" ref-type="fig">figure 4</xref>). Plasma NfL concentrations were also higher in asymptomatic mutation carriers whose CDR+NACC-FTLDsb scores progressed by 1 point, even in the absence of phenoconversion (10.8 ± 8 pg/mL), compared to those whose scores remained stable (6.6 ± 3 pg/mL, <italic toggle="yes">p</italic> = 0.0017, data available from Dryad, efigure 1, <ext-link xlink:href="https://doi.org/10.7272/Q6W957CZ" ext-link-type="uri">doi.org/10.7272/Q6W957CZ</ext-link>).</p>
                <fig position="float" id="F4">
                  <label>Figure 4</label>
                  <caption>
                    <title>Baseline Plasma NfL Concentrations According to Conversion Status by Follow-Up</title>
                    <p>Severity was determined with the CDR Dementia Staging Instrument plus Behavior and Language domains from the National Alzheimer's Disease Coordinating Center Frontotemporal Lobar Degeneration module (CDR+NACC-FTLD). (A–C) Original (Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects [LEFFTDS]/Advancing Research and Treatment in Frontotemporal Lobar Degeneration [ARTFL]) cohort. (D–F) Validation (Genetic Frontotemporal Dementia Initiative [GENFI]) cohort. (A and D) Median baseline neurofilament light chain (NfL) concentrations were higher in asymptomatic mutation carriers (CDR+NACC-FTLD score 0) who progressed to either mild behavioral or cognitive impairment (MBI/MCI; CDR+NACC-FTLD score 0.5) or full phenotype (CDR+NACC-FTLD score ≥1) on follow-up. (B and E) A similar trend was observed in individuals who had MBI/MCI at baseline and when all participants (asymptomatic mutation carriers and those with MBI/MCI) were combined (C and F). Horizontal bars represent median values. Upper and lower quartiles are delimitated by the boxes. Lowest and highest values are indicated by whiskers. Circles = asymptomatic; triangles = MBI/MCI; blue = chromosome 9 open reading frame 72(<italic toggle="yes">C9orf72</italic>) mutation carriers; red = microtubule-associated protein tau (<italic toggle="yes">MAPT</italic>) mutation carriers; yellow = progranulin (<italic toggle="yes">GRN</italic>) mutation carriers;.</p>
                  </caption>
                  <graphic xlink:href="NEUROLOGY2019016329FF4" position="float"/>
                </fig>
                <sec id="s2-3-1">
                  <title>Asymptomatic Mutation Carriers</title>
                  <p>As a continuous variable, baseline NfL related to future decline in CDR+NACC-FTLDsb, CGI-S, and FAS scores (<xref rid="T2" ref-type="table">table 2</xref>). For example, every baseline log NfL 1 pg/mL in asymptomatic mutation carriers was associated with a 1.6-point increase in CDR+NACC-FTLDsb score at year 1 (95% CI 0.75–2.6, <italic toggle="yes">p</italic> &lt; 0.001) and a 2.5-point increase at year 2 (95% CI 1.6–3.4, <italic toggle="yes">p</italic> &lt; 0.001). Similar results were observed when NfL was analyzed as a categorical variable. For example, asymptomatic mutation carriers with high (≥13.6 pg/mL) baseline NfL had CDR+NACC-FTLDsb scores were 1.6 points higher at 1 year (95% CI 1.0–2.2, <italic toggle="yes">p</italic> &lt; 0.001) and 2.4 points higher at 2 years (95% CI 1.8–3.0, <italic toggle="yes">p</italic> &lt; 0.001) than those with low baseline NfL (<xref rid="F5" ref-type="fig">figure 5</xref>). High NfL also related to lower frontal and temporal brain volumes after 2 years. NfL did not predict change in any of the clinical scales or brain volumes in mutation noncarriers.</p>
                  <table-wrap position="float" id="T2">
                    <label>Table 2</label>
                    <caption>
                      <p>Prediction of Disease Progression at 2 Years by Plasma NfL in FTLD-Causing Mutation Carriers, Original Cohort</p>
                    </caption>
                    <graphic xlink:href="NEUROLOGY2019016329TT2" position="float"/>
                  </table-wrap>
                  <fig position="float" id="F5">
                    <label>Figure 5</label>
                    <caption>
                      <title>Prediction of Clinical Progression by Plasma NfL in Familial Frontotemporal Lobar Degeneration</title>
                      <p>(A–C) Original (Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects [LEFFTDS]/Advancing Research and Treatment in Frontotemporal Lobar Degeneration [ARTFL) cohort. (D–F) Validation (Genetic Frontotemporal Dementia Initiative [GENFI]) cohort. Figure shows the results of models using data from all genotypes in each severity group. In the original cohort, patients with high (red; ≥13.6 pg/mL) baseline plasma neurofilament light chain (NfL) showed worse clinical scores at 2 years compared to patients with low (blue; &lt;13.6 pg/mL) NfL, which was supported by NfL level–by–time interaction. This differential predictive effect by NfL level was observed regardless of disease severity, including asymptomatic carriers. Similar results were observed in the validation cohort with a cut point value of 19.8 pg/mL. CDR+NACC-FTLDsb = CDR Dementia Staging Instrument plus Behavior and Language domains from the National Alzheimer's Disease Coordinating Center Frontotemporal Lobar Degeneration module sum of boxes score. *Between-group contrast at that time point, <italic toggle="yes">p</italic> &lt; 0.05.</p>
                    </caption>
                    <graphic xlink:href="NEUROLOGY2019016329FF5" position="float"/>
                  </fig>
                </sec>
                <sec id="s2-3-2">
                  <title>Individuals With MBI/MCI</title>
                  <p>In mutation carriers with MBI/MCI at baseline (CDR+NACC-FTLD score 0.5), baseline NfL was strongly associated with decline at year 2 on CDR+NACC-FTLDsb, MoCA, SEADL, FAS, California Verbal Learning Test immediate recall, Benson recall, digits forward, and semantic fluency scores, but not in brain volumes (<xref rid="T2" ref-type="table">table 2</xref>).</p>
                </sec>
                <sec id="s2-3-3">
                  <title>Full Phenotype</title>
                  <p>In mutation carriers with full phenotype (CDR+NACC-FTLD score ≥1), baseline NfL related to decline in CDR+NACC-FTLDsb, MoCA, and SEADL phonemic fluency scores and brain volume composites after 2 years (<xref rid="T2" ref-type="table">table 2</xref>).</p>
                </sec>
              </sec>
              <sec id="s2-4">
                <title>Validation Cohort</title>
                <p>In the validation cohort, of 297 participants with baseline evaluations, 189 (63.6%) had follow-up year 1 data (available in Dryad, eTable 2, <ext-link xlink:href="https://doi.org/10.7272/Q6W957CZ" ext-link-type="uri">doi.org/10.7272/Q6W957CZ</ext-link>). Plasma NfL concentrations were higher in all symptomatic mutation carriers compared to asymptomatic participants except for CBS (<xref rid="F1" ref-type="fig">figure 1</xref>). Median baseline plasma NfL concentrations were higher in participants with full phenotype (50.6 ± 59 pg/mL) compared to asymptomatic mutation noncarriers (8.8 ± 5 pg/mL), asymptomatic mutation carriers (9.1 ± 8 pg/mL), and those with MBI/MCI (12.1 ± 20 pg/mL, <italic toggle="yes">p</italic> &lt; 0.001) (<xref rid="F2" ref-type="fig">figure 2</xref>). A cut point of ≥19.8 pg/mL discriminated those with full phenotype from asymptomatic individuals or those with MBI/MCI with 87.4% sensitivity, 84.3% specificity, 58.1% positive predictive value, and 96.4% negative predictive value (AUC 0.907, 95% CI 0.861–0.954, <italic toggle="yes">p</italic> &lt; 0.001). This cut point was also a fair discriminator between MBI/MCI and full phenotype (AUC 0.805, 95% CI 0.704–0.906) but not between asymptomatic mutation carriers and those with MBI/MCI (AUC 0.641, 95% CI 0.530–0.752). The proportion of participants with high (≥19.8 pg/mL) NfL was different in each disease severity group (6.1% in asymptomatic mutation noncarriers, 13.9% in asymptomatic mutation carriers, 28.1% in those with MBI/MCI, and 84.3% in individuals with full phenotype, χ<sup>2</sup> = 122.6, <italic toggle="yes">p</italic> &lt; 0.001). In the whole cohort or in mutation carriers only, baseline plasma NfL correlated with CDR+NACC-FTLDsb score, MMSE score, and all neuropsychological measures (eTable 2, <ext-link xlink:href="https://doi.org/10.7272/Q6W957CZ" ext-link-type="uri">doi.org/10.7272/Q6W957CZ</ext-link>).</p>
                <p>Twenty-one mutation carriers phenoconverted after 1 year (15 asymptomatic individuals [13 to MBI/MCI and 2 to full phenotype] and 6 with MBI/MCI to full phenotype). Plasma NfL concentrations were higher in phenoconverters than nonphenoconverters in asymptomatic mutation carriers (14.1 ± 12 pg/mL vs 8.7 ± 6 pg/mL, <italic toggle="yes">p</italic> = 0.038) and those with MBI/MCI (67.3 ± 49 pg/mL vs 9.0 ± 8 pg/mL, <italic toggle="yes">p</italic> = 0.006) (<xref rid="F4" ref-type="fig">figure 4</xref>). Plasma NfL concentrations were also higher in asymptomatic mutation carriers whose CDR+NACC-FTLDsb scores progressed by 1 point, even in the absence of phenoconversion (15.3 ± 33 pg/mL) compared to those whose scores remained stable (8.9 ± 7 pg/mL, <italic toggle="yes">p</italic> = 0.014, efigure 1, <ext-link xlink:href="https://doi.org/10.7272/Q6W957CZ" ext-link-type="uri">doi.org/10.7272/Q6W957CZ</ext-link>). In asymptomatic mutation carriers, baseline NfL predicted worsening at year 1 in CDR+NACC-FTLDsb, MMSE, and Trail-Making Test Part A scores. In participants with MBI/MCI, baseline NfL predicted decline at year 1 in CDR+NACC-FTLDsb, MMSE, Trail-Making Test Part B, and phonemic fluency scores. In those with full phenotype, baseline NfL was associated with subsequent decline in MMSE and Trail-Making Test Part A scores, but the relationships did not survive correction for multiple comparisons (available in Dryad, eTable 3).</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s3">
              <title>Discussion</title>
              <p>We analyzed the prognostic value of plasma NfL concentrations in carriers of the most common FTLD-causing mutations, <italic toggle="yes">C9orf72</italic>, <italic toggle="yes">GRN</italic>, and <italic toggle="yes">MAPT,</italic> over 1–2 years of follow-up, with a special emphasis on asymptomatic mutation carriers and carriers with prodromal disease (MBI/MCI). In 2 independent cohorts, plasma NfL concentrations were strongly related to disease severity with stepwise increases from asymptomatic (clinically normal) through MBI/MCI to full phenotype. At baseline, plasma NfL was strongly correlated with global and functional status, neuropsychological scores, and brain volume. Higher baseline NfL was associated with greater disease severity after 1 or 2 years of follow-up, regardless of disease severity and genotype. Remarkably, this included asymptomatic mutation carriers, in whom plasma NfL was also associated with future clinical decline, allowing identification of individuals at high risk for phenoconversion to symptomatic status within 2 years. Consistent with this finding, NfL also predicted worse clinical and neuropsychological status or more brain atrophy, regardless of disease severity and genotype. These results suggest a role for plasma NfL as a prognostic biomarker in f-FTLD.</p>
              <p>The findings in our original and validation cohorts are consistent with previous studies of serum NfL in f-FTLD and sporadic FTLD. In f-FTLD, serum NfL is associated with disease severity, brain volume, and brain atrophy.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> In symptomatic sporadic FTLD, baseline serum NfL correlated with executive function and brain atrophy, but not with longitudinal change in neuropsychological scores,<sup><xref rid="R17" ref-type="bibr">17</xref></sup> which is similar to what we observed in participants with full phenotype. This study and others<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R35" ref-type="bibr">35</xref></sup> found that in fully symptomatic patients, <italic toggle="yes">GRN</italic> mutation carriers had higher NfL concentrations than <italic toggle="yes">C9or72</italic> and <italic toggle="yes">MAPT</italic> mutation carriers. This does not seem to be due to differences in the number of participants by genotype or the age of symptomatic participants in each genetic group and may reflect a faster rate of neurodegeneration in symptomatic <italic toggle="yes">GRN</italic> mutation carriers. Consistent with previous studies, we observed baseline NfL differences between symptomatic and asymptomatic FTLD mutation carriers and between phenoconverters and nonconverters.<sup><xref rid="R35" ref-type="bibr">35</xref></sup> Similar to those studies, we also observed a large within-group variability in NfL concentrations, regardless of clinical phenotype, disease severity, or genotype. This variability likely explains why median NfL concentrations in asymptomatic mutation carriers were not elevated, yet high concentrations were still associated with future clinical progression. In this group, NfL showed good negative predictive value but poor positive predictive value for phenoconversion. The absolute cutoff values for discrimination between asymptomatic and symptomatic participants were similar to those reported in previous studies based on data from our validation cohort.<sup><xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R35" ref-type="bibr">35</xref></sup> However, 1 study reported a higher cutoff (33 pg/mL)<sup><xref rid="R17" ref-type="bibr">17</xref></sup> that may be explained by the inclusion of older controls and sporadic cases compared to the familial cases reported here.<sup><xref rid="R36" ref-type="bibr">36</xref></sup></p>
              <p>Unlike previous studies, we used the CDR+NACC-FTLD score to stratify patients by level of global impairment, allowing delineation of MBI/MCI, a prodromal state of mild or questionable disease between asymptomatic and full phenotype. The CDR+NACC-FTLD score is more appropriate for patients with FTLD and superior to relying on the clinical phenotype or the traditional Clinical Dementia Rating because the CDR+NACC-FTLD includes measures of behavioral and language impairment.<sup><xref rid="R37" ref-type="bibr">37</xref></sup> We found that baseline NfL concentrations in asymptomatic and MBI/MCI mutation carriers best predicted changes in global and functional scales (i.e., CDR+NACC-FTLDsb, CGI-S, and FAS). In addition, NfL predicted declines in activities of daily living, as measured by the SEADL and FAS scales and several neuropsychological tests, in individuals with MBI/MCI, but not in asymptomatic mutation carriers or full phenotype. The severity-dependent differences in predictive value of baseline NfL are probably attributable to a number of factors. These include a faster rate of functional decline in MBI/MCI, differences in the duration of the MBI/MCI stage depending on the phenotype, and absence of activities of daily living impairments in asymptomatic individuals and a ceiling effect for deterioration in fully symptomatic individuals. Identification of individuals with MBI/MCI, however, may be challenging. The sample sizes for MBI/MCI in both cohorts of this study were relatively small, and the follow-up durations were limited. This may explain why differences in baseline NfL concentrations in participants with MBI/MCI by conversion status were not as strong compared to differences between those with MBI/MCI and asymptomatic or fully symptomatic mutation carriers. These observations might also reflect a short duration in the MBI/MCI state and fluctuation in clinical status over time, with some participants with MBI/MCI progressing to full phenotype and others returning to asymptomatic status. The additional follow-up data that will be collected as part of the ongoing ARTFL LEFFTDS Longitudinal Frontotemporal Dementia (ALLFTD) study<sup><xref rid="R38" ref-type="bibr">38</xref></sup> will improve the understanding of the clinical value of plasma NfL in prodromal f-FTLD.</p>
              <p>Our results suggest that plasma NfL may be a promising endpoint for FTLD clinical trials. A variety of therapies that target the underlying pathologic proteins encoded by the 3 FTLD-causing genes studied here are entering clinical trials for f-FTLD.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> The ultimate goal for these therapies is to prevent disease onset in mutation carriers. A major challenge for testing the efficacy of such interventions is the inability to measure clinically meaningful endpoints in asymptomatic individuals who are at risk for disease. Recent US Food and Drug Administration guidance on developing therapeutics for presymptomatic or early Alzheimer disease suggests that therapies might be approved under an accelerated mechanism on the basis of a biomarker that is “reasonably likely to predict clinical benefit.”<sup><xref rid="R39" ref-type="bibr">39</xref></sup> Our data show associations between plasma NfL concentrations and subsequent functional status, which are considered inherently clinically meaningful, within 2 years of follow-up. Therefore, plasma NfL might be used as a continuous variable endpoint (difference in mean NfL concentration in placebo vs intervention arm) or as a time-to-event endpoint (delay in onset of the sharp rise in NfL that occurs at the transition from the asymptomatic to symptomatic phase of disease). Such an approach was previously used for drugs to treat macular degeneration that were approved for marketing by using optical coherence tomography measurements as endpoints that are highly predictive of future declines in visual acuity.<sup><xref rid="R40" ref-type="bibr">40</xref></sup></p>
              <p>Our study has limitations. NfL is not a pathophysiology-specific biomarker of FTLD, and its elevations in a number of general conditions render it a nonspecific marker of neuronal injury. Future projects should aim at identifying and deploying specific markers of disease activity and severity in FTLD, and we have previously reported the comparative diagnostic value of plasma NfL vs plasma p-tau in FTLD and Alzheimer disease.<sup><xref rid="R41" ref-type="bibr">41</xref></sup> On the basis of work in dominantly inherited Alzheimer disease,<sup><xref rid="R42" ref-type="bibr">42</xref></sup> longitudinal plasma NfL measurements may have better predictive ability for clinical decline than the cross-sectional measures we used. Longitudinal plasma samples of participants of the LEFFTDS and ARTFL projects are being collected, and future projects will examine longitudinal NfL concentrations and their relationship with disease progression. Finally, we found no influence of the <italic toggle="yes">APOE</italic> genotype on NfL concentrations or predictive ability. The analyses, however, did not examine other potential genetic risk factors such as polymorphisms within <italic toggle="yes">MAPT</italic>,<sup><xref rid="R43" ref-type="bibr">43</xref></sup>
<italic toggle="yes">TMEM106B</italic>,<sup><xref rid="R44" ref-type="bibr">44</xref></sup> or <italic toggle="yes">EGFR</italic><sup><xref rid="R45" ref-type="bibr">45</xref></sup> that have been identified as potential modulators of FTLD risk.</p>
              <p>This study adds to a large body of evidence supporting plasma NfL as a useful prognostic biomarker for syndromes associated with FTLD.<sup><xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R35" ref-type="bibr">35</xref>,<xref rid="R46" ref-type="bibr">46</xref>,<xref rid="R47" ref-type="bibr">47</xref></sup> By demonstrating the ability to identify asymptomatic FTLD mutation carriers at risk of progression to symptomatic status over 2 years, our findings provide a strong rationale for developing this biomarker as a potential inclusion criterion or endpoint for prevention studies in asymptomatic f-FTLD mutation carriers.</p>
            </sec>
          </body>
          <back>
            <ack>
              <title>Acknowledgment</title>
              <p>The authors acknowledge the invaluable contributions of the participants and their families in ARTFL, LEFFTDS, and GENFI, as well as the assistance of the support staffs at each of the participating sites. They extend their appreciation to Drs. John Hsiao and Dallas Anderson from the National Institute on Aging and Dr. Margaret Sutherland from the National Institute of Neurological Disorders and Stroke. The manuscript has been reviewed by the ALLFTD Publications Committee for scientific content. Daniel I. Kaufer, MD, is deceased.</p>
            </ack>
            <fn-group>
              <fn fn-type="supplementary-material">
                <p>Class of Evidence: <ext-link xlink:href="http://NPub.org/coe" ext-link-type="uri">NPub.org/coe</ext-link></p>
              </fn>
            </fn-group>
            <sec sec-type="funding">
              <title>Study Funding</title>
              <p content-type="funding">ALLFTD Consortium (LEFFTDS: U01 AG045390; ARTFL: U54 NS092089; ALLFTD: U19AG063911). J.C.R. is supported by National Institute on Aging–NIH: K23AG059888. AMS is supported by National Institute on Aging–NIH: K23AG061253 and Larry L. Hillblom Foundation: 2018-A-025-FEL. Work was also supported by grants U24 AG021886 and U01 AG016976 and the Bluefield Project to Cure FTD. Samples from the National Centralized Repository for Alzheimer’s Disease and Related Dementias, which receives government support under a cooperative agreement grant (U24 AG21886), were used in this study. The Dementia Research Centre is supported by Alzheimer's Research UK, Alzheimer's Society, Brain Research UK, and The Wolfson Foundation. This work was supported by the National Institute for Health Research UCL/H Biomedical Research Centre, the Leonard Wolfson Experimental Neurology Centre Clinical Research Facility, and the UK Dementia Research Institute, which receives its funding from UK DRI Ltd, funded by the UK Medical Research Council, Alzheimer's Society, and Alzheimer's Research UK. J.D.R. is supported by a Medical Research Council Clinician Scientist Fellowship (MR/M008525/1) and has received funding from the National Institute for Health Research Rare Disease Translational Research Collaboration (BRC149/NS/MH). R.C. and C.G. are supported by Frontotemporal Dementia Research Studentships in Memory of David Blechner funded through The National Brain Appeal (RCN 290173). M.B. is supported by a Fellowship award from the Alzheimer’s Society, UK (AS-JF-19a-004-517) and by the UK Dementia Research Institute, which receives its funding from DRI Ltd, funded by the UK Medical Research Council, Alzheimer’s Society, and Alzheimer’s Research UK. R.L. is supported by the Canadian Institutes of Health Research and the Chaire de Recherche sur les Aphasies Primaires Progressives Fondation Famille Lemaire. C.G. is supported by the Swedish Frontotemporal Dementia Initiative Schörling Foundation, Swedish Research Council, JPND Prefrontals, 2015–02926, 2018–02754, Swedish Alzheimer Foundation, Swedish Brain Foundation, Karolinska Institutet Doctoral Funding, KI StratNeuro, Swedish Dementia Foundation, and Stockholm County Council ALF/Region Stockholm. J.L. is supported by Germany’s Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (German Research Foundation, EXC 2145 SyNergy 390857198). This work was also supported by the Medical Research Council UK GENFI grant (MR/M023664/1), the Bluefield Project, the National Institute for Health Research including awards to Cambridge and UCL Biomedical Research Centres, and the JPND GENFI-PROX grant (2019–02248). Several authors of this publication are members of the European Reference Network for Rare Neurologic Diseases, project No. 739510. J.B.R. is supported by NIHR Cambridge Biomedical Research Centre (BRC-1215-20014).</p>
            </sec>
            <sec sec-type="coi-statement">
              <title>Disclosure</title>
              <p>J.C. Rojas is a site principal investigator for clinical trials supported by Eli Lilly and receives support from NIH. P. Wang reports no disclosures relevant to the manuscript. A.M. Staffaroni receives support from the Larry L. Hillblom Foundation and NIH. C. Heller, Y. Cobigo, A. Wolf, S.M. Goh, P.A. Ljubenkov, H.W. Heuer, J.C. Fong reports no disclosures relevant to the manuscript, and J.B. Taylor report no disclosures relevant to the manuscript. E. Veras and L. Song are Quanterix employees. A. Jeromin is an advisor to Quanterix. D. Hanlon is a Quanterix employee. L. Yu, A. Khinikar, R. Sivasankaran, and A. Kieloch are Novartis employees. M.A. Valentin is a Novartis employee and shareholder. A.M. Karydas, L.L. Mitic, R. Pearlman, and J. Kornak report no disclosures relevant to the manuscript. J.H. Kramer receives research support from NIH. B.L. Miller receives research support from NIH and the Bluefield Project to Cure FTD. K. Kantarci served on the Data Safety Monitoring Board for Takeda Global Research &amp; Development Center, Inc and data monitoring boards of Pfizer and Janssen Alzheimer Immunotherapy and reports research support from Avid Radiopharmaceuticals, Eli Lilly, the Alzheimer’s Drug Discovery Foundation, and NIH. D.S. Knopman serves on the Data Safety Monitoring Board of the DIAN-TU study; is a site principal investigator for clinical trials sponsored by Biogen, Lilly, and the University of Southern California; and is funded by NIH. N. Graff-Radford receives royalties from UpToDate and has participated in multicenter therapy studies by sponsored by Biogen, TauRx, AbbVie, Novartis, and Lilly. He receives research support from NIH. L. Petrucelli receives research support from NIH. R. Rademakers receives research funding from NIH and the Bluefield Project to Cure Frontotemporal Dementia. D.C. Irwin receives support from NIH, Brightfocus Foundation, and Penn Institute on Aging. M. Grossman receives grant support from NIH, Avid, and Piramal; participates in clinical trials sponsored by Biogen, TauRx, and Alector; serves as a consultant to Bracco and UCB; and serves on the Editorial Board of <italic toggle="yes">Neurology</italic>®. E.M. Ramos reports no disclosures relevant to the manuscript. G. Coppola receives research support from NIH. M.F. Mendez and Y. Bordelon report no disclosures relevant to the manuscript. B.C. Dickerson receives research support from NIH. N. Ghoshal has participated or is currently participating in clinical trials of antidementia drugs sponsored by the following companies: Bristol Myers Squibb, Eli Lilly/Avid Radiopharmaceuticals, Janssen Immunotherapy, Novartis, Pfizer, Wyeth, SNIFF (Study of Nasal Insulin to Fight Forgetfulness) study, and A4 (Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease) trial. She receives research support from Tau Consortium and Association for Frontotemporal Dementia and is funded by NIH. E.D. Huey receives research support from NIH. I.R. Mackenzie receives research funding from Canadian Institutes of Health Research. B.S. Appleby reports no disclosures relevant to the manuscript. K. Domoto-Reilly serves or has served as an investigator for clinical trials sponsored by Avid Radiopharmaceuticals, Biogen, and Janssen Pharmaceuticals; has served as Advisory Board consultant for Biogen; and receives research support from NIH. G.R. Hsiung has served as an investigator for clinical trials sponsored by AstraZeneca, Eli Lilly, and Roche/Genentech. He receives research support from Canadian Institutes of Health Research and the Alzheimer Society of British Columbia. A.W. Toga receives research support from the NIH and the Alzheimer’s Association. S. Weintraub receives research support from NIH. D.I. Kaufer is deceased; disclosures are not included for this author. D. Kerwin, I. Litvan, and C.U. Onyike report no disclosures relevant to the manuscript. A. Pantelyat receives grant support from the NIH. E.D. Roberson receives research funding from the Bluefield Project to Cure FTD. M.C. Tartaglia and T. Foroud report no disclosures relevant to the manuscript. W. Chen, J. Czerkowicz, and D.L. Graham are Biogen employees. J.C. van Swieten, B. Borroni, R. Sanchez-Valle, F. Moreno, R. Laforce, C. Graff, M. Synofzik, and D. Galimberti report no disclosures relevant to the manuscript. J.B. Rowe reports consultancy for Asceneuron, Biogen, UCB, and SV Healthcare and research grants from Janssen, Lilly, and AZ-Medimmune. M. Masellis, E. Finger, R. Vandenberghe, A. de Mendonça, F. Tagliavini, I. Santana, S. Ducharme, C.R. Butler, and A. Gerhard report no disclosures relevant to the manuscript. J. Levin reports speakers fees from Bayer Vital, consulting fees from Axon Neuroscience, nonfinancial support from Abbvie, compensation for part time CMO from MODAG, author fees from Thieme medical publishers and from W. Kohlhammer GbmH medical publishers, all outside the submitted work. A. Danek, M. Otto, S. Sorbi, D.M, Cash, R.S. Convery, M. Bocchetta, M. Foiani, C.V. Greaves, G. Peakman, L. Russell, I. Swift, and E. Todd report no disclosures relevant to the manuscript. J.D. Rohrer has served as a consultant for Biogen, Ionis, Alector, Wave Life Sciences, and Astex. B.F. Boeve has served as an investigator for clinical trials sponsored by Axovant and Biogen. He receives royalties from the publication of <italic toggle="yes">Behavioral Neurology of Dementia</italic> (Cambridge Medicine, 2009, 2017). He serves on the Scientific Advisory Board of the Tau Consortium. He receives research support from NIH, the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, and the Little Family Foundation. H.J. Rosen has received research support from Biogen Pharmaceuticals, has consulting agreements with Wave Neuroscience and Ionis Pharmaceuticals, and receives research support from NIH. A.L. Boxer receives research support from NIH, the Tau Research Consortium, the Association for Frontotemporal Degeneration, the Bluefield Project to Cure Frontotemporal Dementia, Corticobasal Degeneration Solutions, the Association for Frontotemporal Degeneration, and the Alzheimer's Association. He has served as a consultant for Abbvie, AGTC, Alector, Arkuda, Arvinas, Asceneuron, AZTherapeutics, Bioage, Ionis, Lundbeck, Passage BIO, Regeneron, Samumed, Transposon, and UCB, and received research support from Biogen, Eisai, Eli Lilly, Genentech, Novartis, Roche and TauRx. Go to <ext-link xlink:href="https://n.neurology.org/lookup/doi/10.1212/WNL.0000000000011848" ext-link-type="uri">Neurology.org/N</ext-link><ext-link xlink:href="https://n.neurology.org/lookup/doi/10.1212/WNL.0000000000011848" ext-link-type="uri"/> for full disclosures.</p>
            </sec>
            <app-group>
              <app id="A1">
                <label>Appendix 1</label>
                <title>Authors</title>
                <p>
                  <table-wrap position="anchor" id="TU1">
                    <graphic xlink:href="NEUROLOGY2019016329TTU1" position="float"/>
                  </table-wrap>
                </p>
              </app>
              <app id="A2">
                <label>Appendix 2</label>
                <title>Coinvestigators</title>
                <p>
                  <table-wrap position="anchor" id="TU2">
                    <graphic xlink:href="NEUROLOGY2019016329TTU2" position="float"/>
                  </table-wrap>
                </p>
              </app>
              <app id="A3">
                <label>Appendix 3</label>
                <title>Coinvestigators</title>
                <p>
                  <table-wrap position="anchor" id="TU3">
                    <graphic xlink:href="NEUROLOGY2019016329TTU3" position="float"/>
                  </table-wrap>
                </p>
              </app>
            </app-group>
            <glossary>
              <title>Glossary</title>
              <def-list>
                <def-item>
                  <term id="G1">ALLFTD</term>
                  <def>
                    <p>ARTFL LEFFTDS Longitudinal Frontotemporal Dementia</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G2">ARTFL</term>
                  <def>
                    <p>Advancing Research and Treatment in Frontotemporal Lobar Degeneration</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G3">AUC</term>
                  <def>
                    <p>area under the curve</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G4">bvFTD</term>
                  <def>
                    <p>behavioral variant frontotemporal dementia</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G5">CBS</term>
                  <def>
                    <p>corticobasal syndrome</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G6">CDR+NACC-FTLD</term>
                  <def>
                    <p>CDR Dementia Staging Instrument plus Behavior and Language domains from the National Alzheimer’s Disease Coordinating Center Frontotemporal Lobar Degeneration module</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G7">CGI-S</term>
                  <def>
                    <p>Clinical Global Impression of Severity</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G8">
                    <italic toggle="yes">C90rf72</italic>
                  </term>
                  <def>
                    <p>chromosome 9 open reading frame 72</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G9">CI</term>
                  <def>
                    <p>confidence interval</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G10">FAS</term>
                  <def>
                    <p>Functional Assessment Scale</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G11">FTLD</term>
                  <def>
                    <p>frontotemporal lobar degeneration</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G12">f-FTLD</term>
                  <def>
                    <p>familial FTLD</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G13">FTD/ALS</term>
                  <def>
                    <p>frontotemporal dementia with amyotrophic lateral sclerosis</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G14">GENFI</term>
                  <def>
                    <p>Genetic Frontotemporal Dementia Initiative</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G15">
                    <italic toggle="yes">GRN</italic>
                  </term>
                  <def>
                    <p>progranulin</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G16">LEFFTDS</term>
                  <def>
                    <p>Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G17">
                    <italic toggle="yes">MAPT</italic>
                  </term>
                  <def>
                    <p>microtubule-associated protein tau</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G18">MBI/MCI</term>
                  <def>
                    <p>mild behavioral or cognitive impairment</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G19">MMSE</term>
                  <def>
                    <p>Mini-Mental State Examination</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G20">MoCA</term>
                  <def>
                    <p>Montreal Cognitive Assessment</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G21">NfL</term>
                  <def>
                    <p>neurofilament light chain</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G22">p-NfH</term>
                  <def>
                    <p>phosphorylated neurofilament heavy chain</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G23">PPA</term>
                  <def>
                    <p>primary progressive aphasia</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G24">p-tau</term>
                  <def>
                    <p>phosphorylated tau181</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G25">ROC</term>
                  <def>
                    <p>receiver operating characteristic</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G26">sb</term>
                  <def>
                    <p>sum of boxes</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G27">SEADL</term>
                  <def>
                    <p>Schwab and England Activities of Daily Living</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G28">Simoa</term>
                  <def>
                    <p>single-molecule array</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Blennow</surname><given-names>K</given-names></string-name>, <string-name><surname>Zetterberg</surname><given-names>H</given-names></string-name></person-group>. <article-title>Biomarkers for Alzheimer's disease: current status and prospects for the future</article-title>. <source>J Intern Med</source><year>2018</year>;<volume>284</volume>:<fpage>643</fpage>–<lpage>663</lpage>.<pub-id pub-id-type="pmid">30051512</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name><surname>Jin</surname><given-names>Y</given-names></string-name>, <string-name><surname>Shi</surname><given-names>Z</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The effects of behavioral and psychological symptoms on caregiver burden in frontotemporal dementia, Lewy body dementia, and Alzheimer's disease: clinical experience in China</article-title>. <source>Aging Ment Health</source><year>2017</year>;<volume>21</volume>:<fpage>651</fpage>–<lpage>657</lpage>.<pub-id pub-id-type="pmid">26882509</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Olszewska</surname><given-names>DA</given-names></string-name>, <string-name><surname>Lonergan</surname><given-names>R</given-names></string-name>, <string-name><surname>Fallon</surname><given-names>EM</given-names></string-name>, <string-name><surname>Lynch</surname><given-names>T</given-names></string-name></person-group>. <article-title>Genetics of frontotemporal dementia</article-title>. <source>Curr Neurol Neurosci Rep</source><year>2016</year>;<volume>16</volume>:<fpage>107</fpage>.<pub-id pub-id-type="pmid">27878525</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>DeJesus-Hernandez</surname><given-names>M</given-names></string-name>, <string-name><surname>Mackenzie</surname><given-names>IR</given-names></string-name>, <string-name><surname>Boeve</surname><given-names>BF</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS</article-title>. <source>Neuron</source><year>2011</year>;<volume>72</volume>:<fpage>245</fpage>–<lpage>256</lpage>.<pub-id pub-id-type="pmid">21944778</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baker</surname><given-names>M</given-names></string-name>, <string-name><surname>Mackenzie</surname><given-names>IR</given-names></string-name>, <string-name><surname>Pickering-Brown</surname><given-names>SM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17</article-title>. <source>Nature</source><year>2006</year>;<volume>442</volume>:<fpage>916</fpage>–<lpage>919</lpage>.<pub-id pub-id-type="pmid">16862116</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hutton</surname><given-names>M</given-names></string-name>, <string-name><surname>Lendon</surname><given-names>CL</given-names></string-name>, <string-name><surname>Rizzu</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17</article-title>. <source>Nature</source><year>1998</year>;<volume>393</volume>:<fpage>702</fpage>–<lpage>705</lpage>.<pub-id pub-id-type="pmid">9641683</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Desmarais</surname><given-names>P</given-names></string-name>, <string-name><surname>Rohrer</surname><given-names>JD</given-names></string-name>, <string-name><surname>Nguyen</surname><given-names>QD</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Therapeutic trial design for frontotemporal dementia and related disorders</article-title>. <source>J Neurol Neurosurg Psychiatry</source><year>2019</year>;<volume>90</volume>:<fpage>412</fpage>–<lpage>423</lpage>.<pub-id pub-id-type="pmid">30361298</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bacioglu</surname><given-names>M</given-names></string-name>, <string-name><surname>Maia</surname><given-names>LF</given-names></string-name>, <string-name><surname>Preische</surname><given-names>O</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases</article-title>. <source>Neuron</source><year>2016</year>;<volume>91</volume>:<fpage>56</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">27292537</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sjogren</surname><given-names>M</given-names></string-name>, <string-name><surname>Rosengren</surname><given-names>L</given-names></string-name>, <string-name><surname>Minthon</surname><given-names>L</given-names></string-name>, <string-name><surname>Davidsson</surname><given-names>P</given-names></string-name>, <string-name><surname>Blennow</surname><given-names>K</given-names></string-name>, <string-name><surname>Wallin</surname><given-names>A</given-names></string-name></person-group>. <article-title>Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD</article-title>. <source>Neurology</source><year>2000</year>;<volume>54</volume>:<fpage>1960</fpage>–<lpage>1964</lpage>.<pub-id pub-id-type="pmid">10822437</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rosengren</surname><given-names>LE</given-names></string-name>, <string-name><surname>Karlsson</surname><given-names>JE</given-names></string-name>, <string-name><surname>Karlsson</surname><given-names>JO</given-names></string-name>, <string-name><surname>Persson</surname><given-names>LI</given-names></string-name>, <string-name><surname>Wikkelso</surname><given-names>C</given-names></string-name></person-group>. <article-title>Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF</article-title>. <source>J Neurochem</source><year>1996</year>;<volume>67</volume>:<fpage>2013</fpage>–<lpage>2018</lpage>.<pub-id pub-id-type="pmid">8863508</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Jong</surname><given-names>D</given-names></string-name>, <string-name><surname>Jansen</surname><given-names>RW</given-names></string-name>, <string-name><surname>Pijnenburg</surname><given-names>YA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>CSF neurofilament proteins in the differential diagnosis of dementia</article-title>. <source>J Neurol Neurosurg Psychiatry</source><year>2007</year>;<volume>78</volume>:<fpage>936</fpage>–<lpage>938</lpage>.<pub-id pub-id-type="pmid">17314187</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pijnenburg</surname><given-names>YA</given-names></string-name>, <string-name><surname>Janssen</surname><given-names>JC</given-names></string-name>, <string-name><surname>Schoonenboom</surname><given-names>NS</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls</article-title>. <source>Dement Geriatr Cogn Disord</source><year>2007</year>;<volume>23</volume>:<fpage>225</fpage>–<lpage>230</lpage>.<pub-id pub-id-type="pmid">17290105</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ljubenkov</surname><given-names>PA</given-names></string-name>, <string-name><surname>Staffaroni</surname><given-names>AM</given-names></string-name>, <string-name><surname>Rojas</surname><given-names>JC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory</article-title>. <source>Ann Clin Transl Neurol</source><year>2018</year>;<volume>5</volume>:<fpage>1250</fpage>–<lpage>1263</lpage>.<pub-id pub-id-type="pmid">30349860</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scherling</surname><given-names>CS</given-names></string-name>, <string-name><surname>Hall</surname><given-names>T</given-names></string-name>, <string-name><surname>Berisha</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration</article-title>. <source>Ann Neurol</source><year>2014</year>;<volume>75</volume>:<fpage>116</fpage>–<lpage>126</lpage>.<pub-id pub-id-type="pmid">24242746</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gunnarsson</surname><given-names>M</given-names></string-name>, <string-name><surname>Malmestrom</surname><given-names>C</given-names></string-name>, <string-name><surname>Axelsson</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab</article-title>. <source>Ann Neurol</source><year>2011</year>;<volume>69</volume>:<fpage>83</fpage>–<lpage>89</lpage>.<pub-id pub-id-type="pmid">21280078</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Winter</surname><given-names>B</given-names></string-name>, <string-name><surname>Guenther</surname><given-names>R</given-names></string-name>, <string-name><surname>Ludolph</surname><given-names>AC</given-names></string-name>, <string-name><surname>Hermann</surname><given-names>A</given-names></string-name>, <string-name><surname>Otto</surname><given-names>M</given-names></string-name>, <string-name><surname>Wurster</surname><given-names>CD</given-names></string-name></person-group>. <article-title>Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen</article-title>. <source>J Neurol Neurosurg Psychiatry</source><year>2019</year>;<volume>90</volume>:<fpage>1068</fpage>–<lpage>1069</lpage>.</mixed-citation>
              </ref>
              <ref id="R17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rohrer</surname><given-names>JD</given-names></string-name>, <string-name><surname>Woollacott</surname><given-names>IO</given-names></string-name>, <string-name><surname>Dick</surname><given-names>KM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia</article-title>. <source>Neurology</source><year>2016</year>;<volume>87</volume>:<fpage>1329</fpage>–<lpage>1336</lpage>.<pub-id pub-id-type="pmid">27581216</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Meeter</surname><given-names>LH</given-names></string-name>, <string-name><surname>Dopper</surname><given-names>EG</given-names></string-name>, <string-name><surname>Jiskoot</surname><given-names>LC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Neurofilament light chain: a biomarker for genetic frontotemporal dementia</article-title>. <source>Ann Clin Transl Neurol</source><year>2016</year>;<volume>3</volume>:<fpage>623</fpage>–<lpage>636</lpage>.<pub-id pub-id-type="pmid">27606344</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boeve</surname><given-names>B</given-names></string-name>, <string-name><surname>Bove</surname><given-names>J</given-names></string-name>, <string-name><surname>Brannelly</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The longitudinal evaluation of familial frontotemporal dementia subjects protocol: framework and methodology</article-title>. <source>Alzheimers Dement</source><year>2020</year>;<volume>16</volume>:<fpage>22</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">31636026</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rohrer</surname><given-names>JD</given-names></string-name>, <string-name><surname>Nicholas</surname><given-names>JM</given-names></string-name>, <string-name><surname>Cash</surname><given-names>DM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal Dementia Initiative (GENFI) study: a cross-sectional analysis</article-title>. <source>Lancet Neurol</source><year>2015</year>;<volume>14</volume>:<fpage>253</fpage>–<lpage>262</lpage>.<pub-id pub-id-type="pmid">25662776</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miyagawa</surname><given-names>T</given-names></string-name>, <string-name><surname>Brushaber</surname><given-names>D</given-names></string-name>, <string-name><surname>Syrjanen</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Utility of the global CDR((R)) plus NACC FTLD rating and development of scoring rules: data from the ARTFL/LEFFTDS Consortium</article-title>. <source>Alzheimers Dement</source><year>2020</year>;<volume>16</volume>:<fpage>106</fpage>–<lpage>117</lpage>.<pub-id pub-id-type="pmid">31914218</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heller</surname><given-names>C</given-names></string-name>, <string-name><surname>Foiani</surname><given-names>MS</given-names></string-name>, <string-name><surname>Moore</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia</article-title>. <source>J Neurol Neurosurg Psychiatry</source><year>2020</year>;<volume>91</volume>:<fpage>263</fpage>–<lpage>270</lpage>.<pub-id pub-id-type="pmid">31937580</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Busner</surname><given-names>J</given-names></string-name>, <string-name><surname>Targum</surname><given-names>SD</given-names></string-name></person-group>. <article-title>The Clinical Global Impressions Scale: applying a research tool in clinical practice</article-title>. <source>Psychiatry</source><year>2007</year>;<volume>4</volume>:<fpage>28</fpage>–<lpage>37</lpage>.</mixed-citation>
              </ref>
              <ref id="R24">
                <label>24.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Fahn</surname><given-names>S</given-names></string-name>, <string-name><surname>Elton</surname><given-names>RL</given-names></string-name></person-group>. <article-title>The Unified Parkinson's Disease Rating Scale</article-title>. In: <person-group person-group-type="editor"><string-name><surname>Fahn</surname><given-names>S</given-names></string-name>, <string-name><surname>Marden</surname><given-names>SD</given-names></string-name>, <string-name><surname>Calne</surname><given-names>DB</given-names></string-name>, <string-name><surname>Goldstein</surname><given-names>M</given-names></string-name></person-group>, eds. <source>Recent Developments in Parkinson's Disease</source>. <publisher-name>New Jersey</publisher-name>; <publisher-loc>Macmillan Healthcare</publisher-loc>; Vol 2; <year>1987</year>: <fpage>153</fpage>–<lpage>163</lpage>.</mixed-citation>
              </ref>
              <ref id="R25">
                <label>25.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Schwab</surname><given-names>R</given-names></string-name>, <string-name><surname>England</surname><given-names>A</given-names></string-name></person-group>. <source>Projection Technique for Evaluating Surgery in Parkinson's Disease</source>. <publisher-loc>London</publisher-loc>;<publisher-name>ES Livingston</publisher-name>; <year>1969</year>.</mixed-citation>
              </ref>
              <ref id="R26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pfeffer</surname><given-names>RI</given-names></string-name>, <string-name><surname>Kurosaki</surname><given-names>TT</given-names></string-name>, <string-name><surname>Harrah</surname><given-names>CH</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Chance</surname><given-names>JM</given-names></string-name>, <string-name><surname>Filos</surname><given-names>S</given-names></string-name></person-group>. <article-title>Measurement of functional activities in older adults in the community</article-title>. <source>J Gerontol</source><year>1982</year>;<volume>37</volume>:<fpage>323</fpage>–<lpage>329</lpage>.<pub-id pub-id-type="pmid">7069156</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cummings</surname><given-names>JL</given-names></string-name>, <string-name><surname>Mega</surname><given-names>M</given-names></string-name>, <string-name><surname>Gray</surname><given-names>K</given-names></string-name>, <string-name><surname>Rosenberg-Thompson</surname><given-names>S</given-names></string-name>, <string-name><surname>Carusi</surname><given-names>DA</given-names></string-name>, <string-name><surname>Gornbein</surname><given-names>J</given-names></string-name></person-group>. <article-title>The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia</article-title>. <source>Neurology</source><year>1994</year>;<volume>44</volume>:<fpage>2308</fpage>–<lpage>2314</lpage>.<pub-id pub-id-type="pmid">7991117</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Delis</surname><given-names>DC</given-names></string-name>, <string-name><surname>Kramer</surname><given-names>JH</given-names></string-name>, <string-name><surname>Kaplan</surname><given-names>E</given-names></string-name>, <string-name><surname>Ober</surname><given-names>BA</given-names></string-name></person-group>. <source>California Verbal Learning Test–Adult Version-Manual</source>.<publisher-loc>San Antonio</publisher-loc>; <publisher-name>Psychological Corp</publisher-name>; <year>2000</year>.</mixed-citation>
              </ref>
              <ref id="R29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Possin</surname><given-names>KL</given-names></string-name>, <string-name><surname>Laluz</surname><given-names>VR</given-names></string-name>, <string-name><surname>Alcantar</surname><given-names>OZ</given-names></string-name>, <string-name><surname>Miller</surname><given-names>BL</given-names></string-name>, <string-name><surname>Kramer</surname><given-names>JH</given-names></string-name></person-group>. <article-title>Distinct neuroanatomical substrates and cognitive mechanisms of figure copy performance in Alzheimer's disease and behavioral variant frontotemporal dementia</article-title>. <source>Neuropsychologia</source><year>2011</year>;<volume>49</volume>:<fpage>43</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">21029744</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reitan</surname><given-names>RM</given-names></string-name></person-group>. <article-title>Validity of the Trail-Making Test as an indication of organic brain damage</article-title>. <source>Percept Mot Skills</source><year>1958</year>;<volume>8</volume>:<fpage>271</fpage>–<lpage>276</lpage>.</mixed-citation>
              </ref>
              <ref id="R31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ramos</surname><given-names>EM</given-names></string-name>, <string-name><surname>Dokuru</surname><given-names>DR</given-names></string-name>, <string-name><surname>Van Berlo</surname><given-names>V</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases</article-title>. <source>Alzheimers Dement</source><year>2020</year>;<volume>16</volume>:<fpage>118</fpage>–<lpage>130</lpage>.<pub-id pub-id-type="pmid">31914217</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <label>32.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Staffaroni</surname><given-names>AM</given-names></string-name>, <string-name><surname>Cobigo</surname><given-names>Y</given-names></string-name>, <string-name><surname>Goh</surname><given-names>SM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration</article-title>. <source>Alzheimers Dement</source><year>2020</year>;<volume>16</volume>:<fpage>37</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">31272932</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brambati</surname><given-names>SM</given-names></string-name>, <string-name><surname>Renda</surname><given-names>NC</given-names></string-name>, <string-name><surname>Rankin</surname><given-names>KP</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A tensor based morphometry study of longitudinal gray matter contraction in FTD</article-title>. <source>Neuroimage</source><year>2007</year>;<volume>35</volume>:<fpage>998</fpage>–<lpage>1003</lpage>.<pub-id pub-id-type="pmid">17350290</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>34.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Benjamini</surname><given-names>Y</given-names></string-name>, <string-name><surname>Hochberg</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title>. <source>J R Statist Soc B</source><year>1995</year>;<volume>57</volume>:<fpage>298</fpage>–<lpage>300</lpage>.</mixed-citation>
              </ref>
              <ref id="R35">
                <label>35.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van der Ende</surname><given-names>EL</given-names></string-name>, <string-name><surname>Meeter</surname><given-names>LH</given-names></string-name>, <string-name><surname>Poos</surname><given-names>JM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study</article-title>. <source>Lancet Neurol</source><year>2019</year>;<volume>18</volume>:<fpage>1103</fpage>–<lpage>1111</lpage>.<pub-id pub-id-type="pmid">31701893</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <label>36.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heuer</surname><given-names>HW</given-names></string-name>, <string-name><surname>Wang</surname><given-names>P</given-names></string-name>, <string-name><surname>Rascovsky</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort</article-title>. <source>Alzheimers Dement</source><year>2020</year>;<volume>16</volume>:<fpage>60</fpage>–<lpage>70</lpage>.<pub-id pub-id-type="pmid">31914226</pub-id></mixed-citation>
              </ref>
              <ref id="R37">
                <label>37.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Knopman</surname><given-names>DS</given-names></string-name>, <string-name><surname>Kramer</surname><given-names>JH</given-names></string-name>, <string-name><surname>Boeve</surname><given-names>BF</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Development of methodology for conducting clinical trials in frontotemporal lobar degeneration</article-title>. <source>Brain</source><year>2008</year>;<volume>131</volume>:<fpage>2957</fpage>–<lpage>2968</lpage>.<pub-id pub-id-type="pmid">18829698</pub-id></mixed-citation>
              </ref>
              <ref id="R38">
                <label>38.</label>
                <mixed-citation publication-type="book"><collab>ALLFTLD Study</collab>. <source>ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar Degeneration: A Multisite Research Consortium [online]</source>. Available at: <ext-link xlink:href="https://www.allftd.org/" ext-link-type="uri">allftd.org/</ext-link>. Accessed May 5, 2020.</mixed-citation>
              </ref>
              <ref id="R39">
                <label>39.</label>
                <mixed-citation publication-type="book"><collab>Food and Drug Administration</collab>. <source>Early Alzheimer's Disease: Developing Drugs for Treatment. Guidance for Industry</source>: <publisher-loc>Silver Spring, MD</publisher-loc>: <publisher-name>US Department of Health and Human Services, Center for Drug Evaluation and Research</publisher-name>; <year>2018</year>.</mixed-citation>
              </ref>
              <ref id="R40">
                <label>40.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Csaky</surname><given-names>K</given-names></string-name>, <string-name><surname>Ferris</surname><given-names>F</given-names><suffix>III</suffix></string-name>, <string-name><surname>Chew</surname><given-names>EY</given-names></string-name>, <string-name><surname>Nair</surname><given-names>P</given-names></string-name>, <string-name><surname>Cheetham</surname><given-names>JK</given-names></string-name>, <string-name><surname>Duncan</surname><given-names>JL</given-names></string-name></person-group>. <article-title>Report from the NEI/FDA endpoints workshop on age-related macular degeneration and inherited retinal diseases</article-title>. <source>Invest Ophthalmol Vis Sci</source><year>2017</year>;<volume>58</volume>:<fpage>3456</fpage>–<lpage>3463</lpage>.<pub-id pub-id-type="pmid">28702674</pub-id></mixed-citation>
              </ref>
              <ref id="R41">
                <label>41.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thijssen</surname><given-names>EH</given-names></string-name>, <string-name><surname>La Joie</surname><given-names>R</given-names></string-name>, <string-name><surname>Wolf</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration</article-title>. <source>Nat Med</source><year>2020</year>;<volume>26</volume>:<fpage>387</fpage>–<lpage>397</lpage>.<pub-id pub-id-type="pmid">32123386</pub-id></mixed-citation>
              </ref>
              <ref id="R42">
                <label>42.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Preische</surname><given-names>O</given-names></string-name>, <string-name><surname>Schultz</surname><given-names>SA</given-names></string-name>, <string-name><surname>Apel</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease</article-title>. <source>Nat Med</source><year>2019</year>;<volume>25</volume>:<fpage>277</fpage>–<lpage>283</lpage>.<pub-id pub-id-type="pmid">30664784</pub-id></mixed-citation>
              </ref>
              <ref id="R43">
                <label>43.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoglinger</surname><given-names>GU</given-names></string-name>, <string-name><surname>Melhem</surname><given-names>NM</given-names></string-name>, <string-name><surname>Dickson</surname><given-names>DW</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy</article-title>. <source>Nat Genet</source><year>2011</year>;<volume>43</volume>:<fpage>699</fpage>–<lpage>705</lpage>.<pub-id pub-id-type="pmid">21685912</pub-id></mixed-citation>
              </ref>
              <ref id="R44">
                <label>44.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pottier</surname><given-names>C</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>X</given-names></string-name>, <string-name><surname>Perkerson</surname><given-names>RB</given-names><suffix>III</suffix></string-name>, <etal>et al</etal></person-group>. <article-title>Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study</article-title>. <source>Lancet Neurol</source><year>2018</year>;<volume>17</volume>:<fpage>548</fpage>–<lpage>558</lpage>.<pub-id pub-id-type="pmid">29724592</pub-id></mixed-citation>
              </ref>
              <ref id="R45">
                <label>45.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yokoyama</surname><given-names>JS</given-names></string-name>, <string-name><surname>Karch</surname><given-names>CM</given-names></string-name>, <string-name><surname>Fan</surname><given-names>CC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia</article-title>. <source>Acta Neuropathol</source><year>2017</year>;<volume>133</volume>:<fpage>825</fpage>–<lpage>837</lpage>.<pub-id pub-id-type="pmid">28271184</pub-id></mixed-citation>
              </ref>
              <ref id="R46">
                <label>46.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lu</surname><given-names>CH</given-names></string-name>, <string-name><surname>Macdonald-Wallis</surname><given-names>C</given-names></string-name>, <string-name><surname>Gray</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis</article-title>. <source>Neurology</source><year>2015</year>;<volume>84</volume>:<fpage>2247</fpage>–<lpage>2257</lpage>.<pub-id pub-id-type="pmid">25934855</pub-id></mixed-citation>
              </ref>
              <ref id="R47">
                <label>47.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rojas</surname><given-names>JC</given-names></string-name>, <string-name><surname>Karydas</surname><given-names>A</given-names></string-name>, <string-name><surname>Bang</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Plasma neurofilament light chain predicts progression in progressive supranuclear palsy</article-title>. <source>Ann Clin Transl Neurol</source><year>2016</year>;<volume>3</volume>:<fpage>216</fpage>–<lpage>225</lpage>.<pub-id pub-id-type="pmid">27042681</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
